Logo

Procter & Gamble to Use Osteoporosis Targets Identified by Sequenom

Dec 18, 2003

NEW YORK, Dec. 18 (Genome Web News) - Sequenom has licenced to Procter & Gamble Pharmaceuticals an undisclosed number of osteoporosis targets against which the drug company hopes to develop new therapeutics, the companies said today.

 

P&G will validate targets in osteoporosis biological and animal models to identify screening candidates. Sequenom stands to gain royalties on product sales, and is entitled to receive license and milestone payments. Sequenom will also retain all diagnostic rights to the targets.

Breaking News
The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.